title: Cytolytic induction therapy in heart and lung transplantation: the protagonist opinion.
abstract: From the studies analysed as well as based on our own experience, induction therapy mainly with polyclonal cytolytic agents represents a helpful tool in the individualised immunosuppressive approach, whereas monoclonal induction therapies have to be discussed carefully. Although transplantation is also feasible without cytolytic agents, certain patients at risk will further encourage the need for this valuable therapy also in the future, where new immunosuppressants are available. However, it is anticipated that the application should be conducted on an individual patient basis to achieve optimal individual benefit.
authors.affiliation: Department of Cardiothoracic Surgery, Hannover Medical School, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Wahlers
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016027:Heart Transplantation / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016040:Lung Transplantation / Q000276:immunology* / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D018570:Risk Assessment
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3